Roswell: New Strategy for Treating Pancreatic Cancer

Roswell Park Team Proposes Strategy for Making Pancreatic Tumors Respond to Checkpoint Inhibition New study provides rationale for combining targeted therapies with anti-PD-L1 immunotherapy Most pancreatic cancers do not respond to immune checkpoint inhibitors In lab, combination of CDK4/6 inhibitors and MEK inhibitors slowed tumor growth Targeted

Read more

Roswell Park Team Discovers New Mechanism Driving Pancreatic Cancer

Length of some regions of messenger RNA plays key role in regulating gene expression, cancer growth Role revealed for little-known process known as alternative polyadenylation First large-scale single-cancer analysis of alternative polyadenylation events Changes to length of certain RNA segments can be key prognostic indicator  BUFFALO, N.Y.—

Read more